Price
Target price
€1.23
€1.23
1.490%
0.018
1.490%
-
10.06.25 / Frankfurt
WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cerenis Therapeutics Holding S.A. Stock
There is an upward development for Cerenis Therapeutics Holding S.A. compared to yesterday, with an increase of €0.018 (1.490%).
Our community identified positive and negative aspects for Cerenis Therapeutics Holding S.A. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Cerenis Therapeutics Holding S.A. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerenis Therapeutics Holding S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerenis Therapeutics Holding S.A. | 1.490% | -1.442% | 5.489% | 7.706% | 5.670% | -28.654% | 44.366% |
| Genoway S.A. Inh. | 2.160% | 8.170% | 14.931% | -25.785% | -8.564% | 3.276% | 63.054% |
| Sensorion SA | -4.880% | 5.114% | -1.596% | -50.402% | -38.127% | -4.145% | -54.094% |
| Hybrigenics S.A. | 159.260% | 141.379% | 125.806% | 211.111% | 118.750% | -89.833% | -89.826% |
News
World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein
ABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural